文献速递头颈外科

液体活检用于人乳头瘤病毒相关口咽癌诊断与监测的性能

Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus-Associated Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2023-01-01

这项回顾性观察性队列研究纳入2020年4月至2022年9月常规临床诊疗中接受TTMV-HPV DNA检测的OPSCC患者,诊断队列163例、监测队列290例。诊断队列敏感度91.5%、特异度100%;监测队列敏感度88.4%、特异度100%,阳性预测值100%、阴性预测值99.1%。作者认为需进一步研究验证并探讨将该检测纳入标准临床实践指南。

要点

  • 诊断队列TTMV-HPV DNA敏感度91.5%,特异度100%。
  • 监测队列敏感度88.4%,特异度100%,阳性预测值100%,阴性预测值99.1%。
  • 作者指出HPV相关OPSCC患者中近1/10阴性检测为假阴性。

核心结论

  • 在临床环境中评估时,TTMV-HPV DNA检测在诊断和监测中均显示100%特异度,但诊断队列敏感度为91.5%、监测队列为88.4%,意味着HPV相关OPSCC患者中近1/10的阴性检测为假阴性。
  • 作者认为需要进一步研究验证该检测的性能,若获验证,则需进一步研究将该检测纳入标准临床实践指南。

研究设计与样本

  • 回顾性观察性队列研究,纳入2020年4月至2022年9月常规临床诊疗期间接受TTMV-HPV DNA检测的OPSCC患者。
  • 诊断队列纳入在初始治疗开始前至少完成1次TTMV-HPV DNA检测的患者,共163例,中位(IQR)年龄63(56-68.5)岁,142例(87.1%)为男性。
  • 监测队列纳入在根治性或挽救性治疗完成后至少完成1次TTMV-HPV DNA检测的患者,共290例,中位(IQR)年龄63(57-70)岁,237例(81.7%)为男性。

主要发现

  • 诊断队列163例中,152例(93.3%)为HPV相关OPSCC,11例(6.7%)为HPV阴性OPSCC。
  • 治疗前诊断中TTMV-HPV DNA敏感度为91.5%(95%CI 85.8%-95.4%[139/152次检测]),特异度为100%(95%CI 71.5%-100%[11/11次检测])。
  • 监测队列290例共评估591次检测,23例经分子学确诊病理复发;检测复发的敏感度为88.4%(95%CI 74.9%-96.1%[38/43次检测]),特异度为100%(95%CI 99.3%-100%[548/548次检测])。
  • 阳性预测值为100%(95%CI 90.7%-100%[38/38次检测]),阴性预测值为99.1%(95%CI 97.9%-99.7%[548/553次检测])。
  • 从TTMV-HPV DNA阳性至病理确诊的中位(范围)提前时间为47(0-507)天。

临床怎么用

  • 作者认为需要进一步研究验证该检测的性能,若获验证,则需进一步研究将该检测纳入标准临床实践指南;原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is growing interest in the use of circulating plasma tumor human papillomavirus (HPV) DNA for diagnosis and surveillance of patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Recent advances in the assays, combining the identification of circulating HPV tumor DNA and tumor DNA fragment analysis (tumor tissue-modified viral [TTMV]-HPV DNA), have been shown to be highly accurate. However, use of these newer techniques has been limited to small cohort studies and clinical trials. OBJECTIVE: To establish the clinical efficacy of plasma TTMV-HPV DNA testing in the diagnosis and surveillance of HPV-associated OPSCC in a contemporary clinical setting. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational cohort study included patients with OPSCC who underwent TTMV-HPV DNA testing between April 2020 and September 2022 during the course of routine clinical care. For the diagnosis cohort, patients with at least 1 TTMV-HPV DNA measurement prior to initiation of primary therapy were included. Patients were included in the surveillance cohort if they had at least 1 TTMV-HPV DNA test performed after completion of definitive or salvage therapy. MAIN OUTCOMES AND MEASURES: Per-test performance metrics, including sensitivity, specificity, positive predictive value, and negative predictive value, for TTMV-HPV DNA testing. RESULTS: Of 399 patients included in the analysis, 163 were in the diagnostic cohort (median [IQR] age, 63 [56-68.5] years; 142 [87.1%] male), and 290 were in the surveillance cohort (median [IQR] age, 63 [57-70] years; 237 [81.7%] male). Of the 163 patients in the diagnostic cohort, 152 (93.3%) had HPV-associated OPSCC while 11 (6.7%) had HPV-negative OPSCC. The TTMV-HPV DNA sensitivity in pretreatment diagnosis was 91.5% (95% CI, 85.8%-95.4% [139 of 152 tests]), and the specificity was 100% (95% CI, 71.5%-100% [11 of 11 tests]). In the surveillance cohort, 591 tests conducted in 290 patients were evaluated. A total of 23 patients had molecularly confirmed pathologic recurrences. The TTMV-HPV DNA test demonstrated sensitivity of 88.4% (95% CI, 74.9%-96.1% [38 of 43 tests]) and specificity of 100% (95% CI, 99.3%-100% [548 of 548 tests]) in detecting the recurrences. Positive predictive value was 100% (95% CI, 90.7%-100% [38 of 38 tests]), and negative predictive value was 99.1% (95% CI, 97.9%-99.7% [548 of 553 tests]). The median (range) lead time from positive TTMV-HPV DNA test to pathologic confirmation was 47 (0-507) days. CONCLUSIONS AND RELEVANCE: This cohort study demonstrated that when evaluated in a clinical setting, the TTMV-HPV DNA assay demonstrated 100% specificity in both diagnosis and surveillance. However, the sensitivity was 91.5% for the diagnosis cohort and 88.4% for the surveillance cohort, signifying that nearly 1 in 10 negative tests among patients with HPV-associated OPSCC was a false negative. Additional research is required to validate the assay's performance and, if validated, then further research into the implementation of this assay into standard clinical practice guidelines will be required.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Ferrandino RM, Chen S, Kappauf C, et al. Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus-Associated Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37422913. doi:10.1001/jamaoto.2023.1937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。